Last 9 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.27 | 0.61 | — | 2.19 | 1.10 | 0.01 | 0.51 | 0.49 | 76.86 | — |
| — | +6147.1% | — | +349.2% | -98.6% | — | — | — | — | — | |
| P/B Ratio | — | — | 0.88 | 0.74 | 0.46 | — | 0.13 | 0.18 | 0.65 | — |
| — | — | +567.6% | +299.1% | -29.4% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -60.5% | -350.2% | — | 96.7% | -29.2% | -108.0% | -197.9% | -112.1% | -10135.4% | -1.5% |
| — | -224.1% | — | +186.2% | +99.7% | -7300.8% | — | — | — | — | |
| Operating Margin | -1931.0% | -1445.0% | — | -564.3% | -493.2% | -554.7% | -424.3% | -410.0% | -14981.9% | -218244.9% |
| — | -160.5% | — | -37.6% | +96.7% | +99.7% | — | — | — | — | |
| Net Margin | -17690.2% | -17342.7% | — | -392.9% | -562.4% | -3461.4% | -420.6% | -355.9% | -3548.4% | 213656.6% |
| — | -401.0% | — | -10.4% | +84.1% | -101.6% | — | — | — | — |
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -21.5% | -31.9% | -723.9% | -296.3% | -24.2% | -29.5% | -17.5% | — |
| — | — | +11.2% | -8.5% | -4031.7% | — | — | — | — | — | |
| ROA | -647.1% | -721.3% | -11.5% | -15.8% | -28.5% | -116.4% | -15.6% | -22.0% | -10.9% | 13.7% |
| — | -519.5% | +25.9% | +28.1% | -162.7% | -950.1% | — | — | — | — | |
| ROIC | -295.1% | -192.2% | -114.1% | — | — | -24.0% | -15.6% | -24.1% | -42.5% | — |
| — | -701.5% | -630.9% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.12 | 0.08 | 0.08 | — | 0.24 | 0.14 | 0.11 | — |
| — | — | -50.5% | -43.1% | -26.0% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.58 | 0.58 | 1.25 | 1.39 | 1.41 | 0.18 | 0.26 | 0.41 | 1.11 | 0.05 |
| — | +227.3% | +378.5% | +240.0% | +27.5% | +280.0% | — | — | — | — | |
| Quick Ratio | 0.58 | 0.58 | 1.25 | 1.39 | 1.41 | 0.05 | 0.14 | 0.21 | 0.96 | 0.05 |
| — | +1038.8% | +809.2% | +564.7% | +46.4% | +9.7% | — | — | — | — | |
| Interest Coverage | -50.20 | -4.11 | -83.99 | -53.85 | -26.42 | -63.79 | -25.19 | -118.27 | -145.72 | -1.01 |
| — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AKAN stock.
Akanda Corp.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Akanda Corp.'s current operating margin is -1931.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Akanda Corp.'s business trajectory between earnings reports.